KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Low-concentration bimatoprost 0.01% and timolol 0.1% eye gel versus bimatoprost 0.03% and timolol 0.5% eye drops in open-angle glaucoma or ocular hypertension: a phase III randomised study.

M Francesca Cordeiro, Francesco Oddone, Elena Atanasova Mermeklieva, Dariusz Md Rokicki, Sylvie Nisslé, Piotr Gościniewicz, Ingeborg Stalmans

Br J Ophthalmol 110(4) 403-409

PMID41093358
PMCIDPMC13018773
DOI10.1136/bjo-2025-327555
发表日期2025-10-15
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2:森林图/亚组分析图;Figure 3:图注未提示 KM 曲线;Figure 4:图注未提示 KM 曲线。
摘要

摘要

BACKGROUND/AIMS: To compare the efficacy and safety of a new preservative-free bimatoprost 0.01%/timolol 0.1% fixed combination (BTFC) eye gel with those of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (BTFC eye drops) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). METHODS: In this phase III, international, multi-centre, randomised, parallel group, investigator-masked study, patients receiving a first-line monotherapy, having insufficiently controlled intraocular pressure (IOP) and requiring dual therapy were randomised to receive either BTFC eye gel or BTFC eye drops once daily for 12 weeks. The primary efficacy endpoint was the change in IOP from baseline to week 12 at 08:00 in the assessed eye. Further efficacy and safety endpoints were assessed as secondary outcomes. RESULTS: The mean±SD change in IOP from baseline to week 12 at 08:00 was -10.96±3.43 mmHg for the BTFC eye gel group and -11.14±3.56 mmHg for the BTFC eye drop group. The least-squares mean difference (BTFC eye gel minus BTFC eye drops) was -0.04±0.24 mmHg (95% CI -0.51 to 0.43 mmHg), with the upper bound of the 95% CI lower than the predefined margin of +1.5 mmHg at week 12 at 08:00. Similar IOP-lowering efficacy was demonstrated at all other timepoints. The safety profile was comparable between the treatment groups. No patients in the BTFC eye gel group discontinued the study due to a treatment-related adverse event compared with 8 (2.9%) patients in the BTFC eye drop group. CONCLUSION: Low-concentration BTFC eye gel can be considered as a safe and effective treatment in the therapeutic management of glaucoma and OHT.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Overall design of the study. D, day; W, week
非 KM Figure
Figure 2(A) Mean±SD of IOP at screening, baseline, week 6 and week 12 in the study eye (mITT set). (B) Forest plot for the adjusted mean differences (BTFC eye gel minus BTFC eye drops) of the change in IOP from baseline (mmHg) in the study eye (mITT set). BTFC eye drop, bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution; BTFC eye gel, bimatoprost 0.01%/timolol 0.1% fixed combination; LS, lease squares; mITT, modified intent-to-treat; IOP, intraocular pressure.
非 KM Figure
Figure 3Percentage of patients with moderate or severe conjunctival hyperaemia (grade ≥3 on the McMonnies scale) at baseline, week 6 and week 12. BTFC eye drop, bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution; BTFC eye gel, bimatoprost 0.01%/timolol 0.1% fixed combination eye gel
非 KM Figure
Figure 4(A) Ocular tolerance assessment of the study treatment at week 6 was considered very satisfactory or satisfactory by the investigators or patients. (B) Ocular tolerance assessment of the study treatment at week 12 was considered very satisfactory or satisfactory by the investigators or patients. *Significant difference between the groups.
非 KM Figure